肺癌有创纵隔分期在不同医院间的差异:一项多中心区域研究
该回顾性研究分析了2011至2013年华盛顿州5家医院(4家社区医院和1家学术医院)接受肺癌切除术的406例患者,发现有创纵隔分期总使用率为66%(95%CI 61%-71%),但各医院间差异显著,其中2家医院显著高于总体平均水平,2家医院显著低于总体平均水平。
要点
- 在5家医院406例接受肺癌切除术的患者中,有创纵隔分期的总体使用率为66%(95%CI 61%-71%)。
- 2家医院的有创纵隔分期率显著高于总体平均水平(94%和84%),另有2家医院显著低于总体平均水平(31%和17%)。
- 作者认为,未来旨在理解这种差异原因的研究可能为质量改进举措提供信息,或促成新的分期算法的开发。
核心结论
- 为肺癌患者提供外科治疗的医院之间,有创纵隔分期的使用率存在显著差异。
- 未来旨在理解这种差异原因的研究可能为质量改进举措提供信息,或促成新的分期算法的开发。
研究设计与样本
- 回顾性研究,数据来自华盛顿州外科临床结局与评估项目(Surgical Clinical Outcomes and Assessment Program),纳入2011年至2013年接受肺癌切除术的患者。
- 共纳入406例患者,来自5家医院(4家社区医院和1家学术医院),平均年龄68岁,69%为临床IA期,67%接受肺叶切除术。
- 有创纵隔分期包括纵隔镜检查和/或支气管内/食管超声引导下淋巴结穿刺。
- 采用混合效应模型以减少任何单一医院小样本量的影响,并校正医院间临床IA期疾病频率的差异。
主要发现
- 有创纵隔分期的总体使用率为66%(95%CI 61%-71%)。
- 2家医院的有创纵隔分期率显著高于总体平均水平:94%(95%CI 89%-96%)和84%(95%CI 78%-88%)。
- 2家医院的有创纵隔分期率显著低于总体平均水平:31%(95%CI 21%-44%)和17%(95%CI 7%-36%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Prior studies have reported underuse of-but not variability in-invasive mediastinal staging in the pretreatment evaluation of patients with lung cancer. We sought to compare rates of invasive mediastinal staging for lung cancer across hospitals participating in a regional quality improvement and research collaborative. METHODS: We conducted a retrospective study (2011-2013) of patients undergoing resected lung cancer from the Surgical Clinical Outcomes and Assessment Program in Washington State. Invasive mediastinal staging included mediastinoscopy and/or endobronchial/esophageal ultrasound-guided nodal aspiration. We used a mixed-effects model to mitigate the influence of small sample sizes at any 1 hospital on rates of invasive staging and to adjust for hospital-level differences in the frequency of clinical stage IA disease. RESULTS: A total of 406 patients (mean age, 68 years; 69% clinical stage IA; and 67% lobectomy) underwent resection at 5 hospitals (4 community and 1 academic). Invasive staging occurred in 66% of patients (95% confidence interval [CI], 61%-71%). CI inspection revealed that 2 hospitals performed invasive staging significantly more often than the overall average (94%, [95% CI, 89%-96%] and 84% [95% CI, 78%-88%]), whereas 2 hospitals performed invasive staging significantly less often than overall average (31% [95% CI, 21%-44%] and 17% [95% CI, 7%-36%]). CONCLUSIONS: Rates of invasive mediastinal staging varied significantly across hospitals providing surgical care for patients with lung cancer. Future studies that aim to understand the reasons underlying variability in care may inform quality improvement initiatives or lead to the development of novel staging algorithms.
引用
- Thornblade LW, Wood DE, Mulligan MS, et al. Variability in invasive mediastinal staging for lung cancer: A multicenter regional study. J Thorac Cardiovasc Surg. 2018. PMID: 29534904. doi:10.1016/j.jtcvs.2017.12.138
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。